StockNews.AI
CVS
Benzinga
110 days

CVS Caremark To Place Novo Nordisk's Wegovy On Preferred Coverage For GLP-1 Weight Loss Treatment

1. CVS will prefer Wegovy on its formularies from July 2025. 2. Novo Nordisk promotes Wegovy for obesity treatment and cardiovascular risk reduction. 3. Wegovy is priced at $499/month for self-paying patients. 4. Novo Nordisk explores ways to enhance Wegovy access for CVS customers. 5. Hims & Hers offer Wegovy prescriptions at $599/month.

4m saved
Insight
Article

FAQ

Why Bullish?

CVS's endorsement of Wegovy is likely to boost its sales, aligning CVS with a growing market in obesity management.

How important is it?

The article emphasizes CVS's strategic move that taps into a lucrative segment, influencing investor perception and market positioning.

Why Long Term?

The formulary change may take time to manifest financially, but it sets CVS up for growth in the growing GLP-1 market.

Related Companies

Related News